Long-Term Changes in Leptin, Chemerin, and Ghrelin Levels Following Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy



Published reports showed conflicting results regarding the sustained alterations in leptin, chemerin, and ghrelin concenratios after metabolic surgery. Therefore, we performed the present work to contrast the alterations in leptin, chemerin, and ghrelin levels one year after Roux-en-Y gastric bypass (RYGB) versus laparoscopic sleeve gastrectomy (LSG).


The present research is a prospective, comparative one that followed 100 cases for whom RYGB or LSG was done. We assessed the serum values of adiposity-associated mediators, including adipokcytokines (leptin and active chemerin) and gastrointestinal hormones (total ghrelin). The primary outcome in the present study was the alterations in leptin, chemerin, and ghrelin values at 12 months after RYGB and LSG.


The serum leptin level decreased significantly in the LSG group with a mean change of − 170.8 ± 29.4 ng/mL (p < 0.001). Similarly, the serum leptin concentration decreased significantly in the RYGB group, with a mean change of − 165.42 ± 53.4 (p < 0.001). In addition, the mean reduction in baseline chemerin levels 12 months after the operation was considerable in the LSG cohort (− 23.24 ± 9.5 ng/mL) and RYGB group (− 22.12 ± 15.9 ng/mL). The ghrelin values demonstrated a notable reduction in the LSG cohort (− 0.083 ± 0.11 pg/mL) and RYGB group (− 0.068 ± 0.097 pg/mL). However, the changes in the three hormones were not substantially different between both groups (p > 0.05).


Both RYGB and LSG result in a considerable, comparable decrease in the postoperative serum concentrations of leptin, chemerin, and ghrelin.

This is a preview of subscription content, access via your institution.


  1. 1.

    Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA - J. Am. Med. Assoc. 2016. p. 2284–91.

  2. 2.

    Ogden CL, Carroll MD, Lawman HG, Fryar CD, Kruszon-Moran D, Kit BK, et al. Trends in obesity prevalence among children and adolescents in the United States, 1988-1994 through 2013-2014. JAMA - J. Am. Med. Assoc. 2016. p. 2292–9.

  3. 3.

    World Health Organization. Global status report 2014. Health statistics and information systems. Geneva WHO. 2011.

  4. 4.

    Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;

  5. 5.

    Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world—a growing challenge. N Engl J Med. 2007;356:213–5.

    CAS  Article  Google Scholar 

  6. 6.

    Rajan T, Menon V. Psychiatric disorders and obesity: a review of association studies. J Postgrad Med. 2017;63:182.

    CAS  Article  Google Scholar 

  7. 7.

    Caudwell P, Hopkins M, King NA, Stubbs RJ, Blundell JE. Exercise alone is not enough: weight loss also needs a healthy (Mediterranean) diet? Public Health Nutr [Internet]. 2009 [cited 2019 Aug 2];12:1663–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19689837

  8. 8.

    Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. Obstet. Gynecol. Surv. 2009. p. 460–2.

  9. 9.

    Velazquez A, Apovian CM. Pharmacological management of obesity. Minerva Endocrinol. 2018. p. 356–66.

  10. 10.

    Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nat. Rev. Gastroenterol. Hepatol. 2017. p. 160–9.

  11. 11.

    Angrisani L, Santonicola A, Iovino P, et al. Bariatric surgery worldwide 2013. Obes Surg. 2015;25:1822–32.

    CAS  Article  Google Scholar 

  12. 12.

    Welbourn R, Hollyman M, Kinsman R, et al. Bariatric surgery worldwide: baseline demographic description and one-year outcomes from the Fourth IFSO Global Registry Report 2018. Obes Surg. 2019;29(3):782–95.

    Article  Google Scholar 

  13. 13.

    Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 2003. p. 561–6.

  14. 14.

    Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 2005. p. 939–49.

  15. 15.

    Cao H. Adipocytokines in obesity and metabolic disease. J. Endocrinol. 2014.

  16. 16.

    Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev. 2006;27:762–78.

    CAS  Article  Google Scholar 

  17. 17.

    Lord GM, Matarese G, Howard JK, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394:897–901.

    CAS  Article  Google Scholar 

  18. 18.

    Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001;104:3052–6.

    CAS  Article  Google Scholar 

  19. 19.

    Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009;94:3085–8.

    CAS  Article  Google Scholar 

  20. 20.

    Monteleone P, Maj M. Dysfunctions of leptin, ghrelin, BDNF and endocannabinoids in eating disorders: beyond the homeostatic control of food intake. Psychoneuroendocrinology. 2013. p. 312–30.

  21. 21.

    Dimitriadis E, Daskalakis M, Kampa M, et al. Alterations in gut hormones after laparoscopic sleeve gastrectomy: a prospective clinical and laboratory investigational study. Ann Surg. 2013;257:647–54.

    Article  Google Scholar 

  22. 22.

    Makris MC, Alexandrou A, Papatsoutsos EG, Malietzis G, Tsilimigras DI, Guerron AD, et al. Ghrelin and obesity: identifying gaps and dispelling myths. A reappraisal. In Vivo (Brooklyn). 2017. p. 1047–50.

  23. 23.

    von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;

  24. 24.

    Ahima RS, Saper CB, Flier JS, et al. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol. 2000;21:263–307.

    CAS  Article  Google Scholar 

  25. 25.

    Wu N, Tan HR. Leptin receptor and its relations with obesity. Chinese Pharmacol Bull. 2004;20:1334–6.

    CAS  Google Scholar 

  26. 26.

    Gruzdeva O, Borodkina D, Uchasova E, Dyleva Y, Barbarash O. Leptin resistance: underlying mechanisms and diagnosis. Diabetes, Metab. Syndr. Obes. Targets Ther. 2019.

  27. 27.

    Holtkamp K, Hebebrand J, Mika C, et al. High serum leptin levels subsequent to weight gain predict renewed weight loss in patients with anorexia nervosa. Psychoneuroendocrinology. 2004;29:791–7.

    CAS  Article  Google Scholar 

  28. 28.

    Matarese G, La Cava A, Sanna V, Lord GM, Lechler RI, Fontana S, et al. Balancing susceptibility to infection and autoimmunity: a role for leptin? Trends Immunol. 2002. p. 182–7.

  29. 29.

    Montani JP, Antic V, Yang Z, et al. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes. 2002;26:S28–38.

    CAS  Article  Google Scholar 

  30. 30.

    Ren J. Leptin and hyperleptinemia-from friend to foe for cardiovascular function. J. Endocrinol. 2004. p. 1–10.

  31. 31.

    Forny-Germano L, De Felice FG, Do Nascimento Vieira MN. The role of leptin and adiponectin in obesity-associated cognitive decline and Alzheimer’s disease. Front Neurosci. 2019;

  32. 32.

    Geloneze B, Tambascia MA, Pareja JC, et al. Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes. Obes Surg. 2001;11:693–8.

    CAS  Article  Google Scholar 

  33. 33.

    Kalinowski P, Paluszkiewicz R, Wróblewski T, et al. Ghrelin, leptin, and glycemic control after sleeve gastrectomy versus Roux-en-Y gastric bypass—results of a randomized clinical trial. Surg Obes Relat Dis. 2017;13:181–8.

    Article  Google Scholar 

  34. 34.

    Terra X, Auguet T, Guiu-Jurado E, et al. Long-term changes in leptin, chemerin and ghrelin levels following different bariatric surgery procedures: Roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg. 2013;23:1790–8.

    Article  Google Scholar 

  35. 35.

    Woelnerhanssen B, Peterli R, Steinert RE, Peters T, Borbély Y, Beglinger C. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy--a prospective randomized trial. Surg Obes Relat Dis [Internet]. [cited 2019 Aug 8];7:561–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21429816

  36. 36.

    Rourke JL, Dranse HJ, Sinal CJ. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes. Rev. 2013. p. 245–62.

  37. 37.

    Bozaoglu K, Curran JE, Stocker CJ, et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab. 2010;95:2476–85.

    CAS  Article  Google Scholar 

  38. 38.

    Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 2011. p. 2111–7.

  39. 39.

    Sell H, Divoux A, Poitou C, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2010;95:2892–6.

    CAS  Article  Google Scholar 

  40. 40.

    Ress C, Tschoner A, Engl J, et al. Effect of bariatric surgery on circulating chemerin levels. Eur J Clin Invest. 2010;40:277–80.

    CAS  Article  Google Scholar 

  41. 41.

    Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992–5.

    CAS  Article  Google Scholar 

  42. 42.

    Callahan HS, Cummings DE, Pepe MS, et al. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab. 2004;89:1319–24.

    CAS  Article  Google Scholar 

  43. 43.

    Piche T. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. Nutr. Clin. Metab. 2002. p. 219–20.

  44. 44.

    Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.

    Article  Google Scholar 

  45. 45.

    Erol V, Aydın C, Uğurlu L, Turgut E, Yalçın H, Demet İnce F. Changes in ghrelin, leptin and insulin levels after laparoscopic sleeve gastrectomy Laparoskopik sleeve gastrektomi sonrası grelin, leptin ve insülin düzeylerindeki değişiklikler. Res. Artic. / Araştırma Makal. Ege J. Med. / Ege Tıp Derg. 2019.

  46. 46.

    Tritos NA, Mun E, Bertkau A, et al. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res. 2003;11:919–24.

    CAS  Article  Google Scholar 

  47. 47.

    Geloneze B, Tambascia MA, Pilla VF, et al. Ghrelin: A gut-brain hormone. Effect of gastric bypass surgery. Obes Surg. 2003;13:17–22.

    Article  Google Scholar 

  48. 48.

    Pournaras DJ, Le Roux CW. Ghrelin and metabolic surgery. Int. J. Pept. 2010.

  49. 49.

    Santiago-Fernández C, García-Serrano S, Tome M, Valdes S, Ocaña-Wilhelmi L, Rodríguez-Cañete A, et al. Ghrelin levels could be involved in the improvement of insulin resistance after bariatric surgery. Endocrinol diabetes y Nutr [Internet]. [cited 2019 Aug 8];64:355–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28745606

  50. 50.

    Stoeckli R, Clianda R, Langer I, et al. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res. 2004;12:346–50.

    CAS  Article  Google Scholar 

  51. 51.

    Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab. 2005;90:359–65.

    CAS  Article  Google Scholar 

  52. 52.

    Le Roux CW, Aylwin SJB, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108–14.

    Article  Google Scholar 

  53. 53.

    Frühbeck G, Rotellar F, Hernández-Lizoain JL, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg. 2004;14:1208–15.

    Article  Google Scholar 

  54. 54.

    Faraj M, Havel PJ, Phélis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88:1594–602.

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Ahmed Abdallah Salman.

Ethics declarations

Informed consents were obtained from all patients included in the study

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethics Approval

This study was approved by the institutional review board/clinical medical research ethics committee.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Salman, M.A., El-ghobary, M., Soliman, A. et al. Long-Term Changes in Leptin, Chemerin, and Ghrelin Levels Following Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy. OBES SURG 30, 1052–1060 (2020). https://doi.org/10.1007/s11695-019-04254-z

Download citation


  • Bariatric operations
  • Adipokines
  • Leptin
  • Ghrelin
  • Chemerin